Review




Structured Review

Millipore anti d1 receptor antibody
Anti D1 Receptor Antibody, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti d1 receptor antibody/product/Millipore
Average 86 stars, based on 1 article reviews
anti d1 receptor antibody - by Bioz Stars, 2025-04
86/100 stars

Images



Similar Products

86
Pfizer Inc d1r d5r agonists
TRANSCENDS Study Overview. A. Translational Framework for Spatial Working Memory (sWM) Neural Biomarkers Overview. The translational framework designed for the TRANSCENDS study is that <t>D1R/D5R</t> agonists improve working memory in schizophrenia by restoring deficient inhibitory tuning within cortical microcircuits. A) i) Spatial working memory task from Cho et al. . The task has 4 conditions: Motor, Spatial Working Memory (No Distractor), Distractor Near (20° or 40° distance), Distractor Far (60° or 80° distance), and provides a continuous measure of sWM precision; ii) the sWM task is optimized for probing human cognitive circuits using fMRI. Panel refers to from Cho et al showing regions activated by sWM across encoding and delay epochs, including frontoparietal circuitry; iii) sWM task is grounded in studies of primate physiology, which suggest that optimal stimulation of the D1R occurs in a dose-dependent, inverted-U manner to support sWM (adapted from Goldman-Rakic, Arnsten, and colleagues ( , , )). B. The TRANSCENDS informatics infrastructure is designed to provide automated data quality assurance, interoperable electronic data capture (EDC), validated systems integration, seamless data sharing, and an analytics platform for biomarker readout. C. Overview of the clinical trial design, which uses a double-blind multi-dose strategy across five separate test days to examine dose-dependent effects of D1R/D5R partial agonism on working memory neural circuits.
D1r D5r Agonists, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/d1r d5r agonists/product/Pfizer Inc
Average 86 stars, based on 1 article reviews
d1r d5r agonists - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

86
Revvity human f st d1 receptor
TRANSCENDS Study Overview. A. Translational Framework for Spatial Working Memory (sWM) Neural Biomarkers Overview. The translational framework designed for the TRANSCENDS study is that <t>D1R/D5R</t> agonists improve working memory in schizophrenia by restoring deficient inhibitory tuning within cortical microcircuits. A) i) Spatial working memory task from Cho et al. . The task has 4 conditions: Motor, Spatial Working Memory (No Distractor), Distractor Near (20° or 40° distance), Distractor Far (60° or 80° distance), and provides a continuous measure of sWM precision; ii) the sWM task is optimized for probing human cognitive circuits using fMRI. Panel refers to from Cho et al showing regions activated by sWM across encoding and delay epochs, including frontoparietal circuitry; iii) sWM task is grounded in studies of primate physiology, which suggest that optimal stimulation of the D1R occurs in a dose-dependent, inverted-U manner to support sWM (adapted from Goldman-Rakic, Arnsten, and colleagues ( , , )). B. The TRANSCENDS informatics infrastructure is designed to provide automated data quality assurance, interoperable electronic data capture (EDC), validated systems integration, seamless data sharing, and an analytics platform for biomarker readout. C. Overview of the clinical trial design, which uses a double-blind multi-dose strategy across five separate test days to examine dose-dependent effects of D1R/D5R partial agonism on working memory neural circuits.
Human F St D1 Receptor, supplied by Revvity, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human f st d1 receptor/product/Revvity
Average 86 stars, based on 1 article reviews
human f st d1 receptor - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

86
FRANCE BIOIMAGING flag snaptag d1 receptor
TRANSCENDS Study Overview. A. Translational Framework for Spatial Working Memory (sWM) Neural Biomarkers Overview. The translational framework designed for the TRANSCENDS study is that <t>D1R/D5R</t> agonists improve working memory in schizophrenia by restoring deficient inhibitory tuning within cortical microcircuits. A) i) Spatial working memory task from Cho et al. . The task has 4 conditions: Motor, Spatial Working Memory (No Distractor), Distractor Near (20° or 40° distance), Distractor Far (60° or 80° distance), and provides a continuous measure of sWM precision; ii) the sWM task is optimized for probing human cognitive circuits using fMRI. Panel refers to from Cho et al showing regions activated by sWM across encoding and delay epochs, including frontoparietal circuitry; iii) sWM task is grounded in studies of primate physiology, which suggest that optimal stimulation of the D1R occurs in a dose-dependent, inverted-U manner to support sWM (adapted from Goldman-Rakic, Arnsten, and colleagues ( , , )). B. The TRANSCENDS informatics infrastructure is designed to provide automated data quality assurance, interoperable electronic data capture (EDC), validated systems integration, seamless data sharing, and an analytics platform for biomarker readout. C. Overview of the clinical trial design, which uses a double-blind multi-dose strategy across five separate test days to examine dose-dependent effects of D1R/D5R partial agonism on working memory neural circuits.
Flag Snaptag D1 Receptor, supplied by FRANCE BIOIMAGING, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flag snaptag d1 receptor/product/FRANCE BIOIMAGING
Average 86 stars, based on 1 article reviews
flag snaptag d1 receptor - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

86
Dawley Inc d1r
Psychedelic research in a rodent model.
D1r, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/d1r/product/Dawley Inc
Average 86 stars, based on 1 article reviews
d1r - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

86
Millipore anti d1 receptor antibody
Psychedelic research in a rodent model.
Anti D1 Receptor Antibody, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti d1 receptor antibody/product/Millipore
Average 86 stars, based on 1 article reviews
anti d1 receptor antibody - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology d1r antibody
Psychedelic research in a rodent model.
D1r Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/d1r antibody/product/Santa Cruz Biotechnology
Average 94 stars, based on 1 article reviews
d1r antibody - by Bioz Stars, 2025-04
94/100 stars
  Buy from Supplier

86
Atlas Antibodies d1r
Psychedelic research in a rodent model.
D1r, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/d1r/product/Atlas Antibodies
Average 86 stars, based on 1 article reviews
d1r - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

86
Millipore d1r agonist skf 38393 hydrochloride
Psychedelic research in a rodent model.
D1r Agonist Skf 38393 Hydrochloride, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/d1r agonist skf 38393 hydrochloride/product/Millipore
Average 86 stars, based on 1 article reviews
d1r agonist skf 38393 hydrochloride - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

Image Search Results


TRANSCENDS Study Overview. A. Translational Framework for Spatial Working Memory (sWM) Neural Biomarkers Overview. The translational framework designed for the TRANSCENDS study is that D1R/D5R agonists improve working memory in schizophrenia by restoring deficient inhibitory tuning within cortical microcircuits. A) i) Spatial working memory task from Cho et al. . The task has 4 conditions: Motor, Spatial Working Memory (No Distractor), Distractor Near (20° or 40° distance), Distractor Far (60° or 80° distance), and provides a continuous measure of sWM precision; ii) the sWM task is optimized for probing human cognitive circuits using fMRI. Panel refers to from Cho et al showing regions activated by sWM across encoding and delay epochs, including frontoparietal circuitry; iii) sWM task is grounded in studies of primate physiology, which suggest that optimal stimulation of the D1R occurs in a dose-dependent, inverted-U manner to support sWM (adapted from Goldman-Rakic, Arnsten, and colleagues ( , , )). B. The TRANSCENDS informatics infrastructure is designed to provide automated data quality assurance, interoperable electronic data capture (EDC), validated systems integration, seamless data sharing, and an analytics platform for biomarker readout. C. Overview of the clinical trial design, which uses a double-blind multi-dose strategy across five separate test days to examine dose-dependent effects of D1R/D5R partial agonism on working memory neural circuits.

Journal: medRxiv

Article Title: A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial

doi: 10.1101/2025.04.18.25326082

Figure Lengend Snippet: TRANSCENDS Study Overview. A. Translational Framework for Spatial Working Memory (sWM) Neural Biomarkers Overview. The translational framework designed for the TRANSCENDS study is that D1R/D5R agonists improve working memory in schizophrenia by restoring deficient inhibitory tuning within cortical microcircuits. A) i) Spatial working memory task from Cho et al. . The task has 4 conditions: Motor, Spatial Working Memory (No Distractor), Distractor Near (20° or 40° distance), Distractor Far (60° or 80° distance), and provides a continuous measure of sWM precision; ii) the sWM task is optimized for probing human cognitive circuits using fMRI. Panel refers to from Cho et al showing regions activated by sWM across encoding and delay epochs, including frontoparietal circuitry; iii) sWM task is grounded in studies of primate physiology, which suggest that optimal stimulation of the D1R occurs in a dose-dependent, inverted-U manner to support sWM (adapted from Goldman-Rakic, Arnsten, and colleagues ( , , )). B. The TRANSCENDS informatics infrastructure is designed to provide automated data quality assurance, interoperable electronic data capture (EDC), validated systems integration, seamless data sharing, and an analytics platform for biomarker readout. C. Overview of the clinical trial design, which uses a double-blind multi-dose strategy across five separate test days to examine dose-dependent effects of D1R/D5R partial agonism on working memory neural circuits.

Article Snippet: Non-human primate studies conducted by Pfizer describe dose-related improvements in sWM , and with chronic intermittent administration, even lower doses of D1R/D5R agonists that were without initial benefit also exhibited procognitive effects ( ).

Techniques: Biomarker Assay

Psychedelic research in a rodent model.

Journal: Advanced Science

Article Title: Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives

doi: 10.1002/advs.202413786

Figure Lengend Snippet: Psychedelic research in a rodent model.

Article Snippet: ERK, D1R, and c‐fos , , 50 mg kg −1 , IP (Once a day for 7 d) , Male Sprague Dawley rats , Ketamine abuse model was established administration of ketamine IP injection. , Ketamine abusing enhanced the anxious behavior and disrupted NAc , [ ] .

Techniques: Activation Assay, Gene Expression, Activity Assay, Conditioned Place Preference, Injection, Transmission Assay, Mutagenesis, Mouse Assay, Microinjection, Saline

Overview of psychedelic drugs and receptors in mental disorders. Psychedelic drugs, including psilocybin, MDMA, LSD, ketamine, ibogaine, and ayahuasca (DMT as an active component in ayahuasca brew), have renewed interest in treating psychiatric disorders. Emerging psychedelics are harnessed to restore symptoms against poor response rates to traditional medications, such as major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive‒compulsive disorder, autism spectrum disorder (ASD), and substance use disorders (SUD) (e.g., alcohol and opioid). Some psychedelics interact collectively with diverse types or subtypes of receptors, and vice versa, owing to the structural similarities of cognate neurotransmitters. The psychedelics confer potentiation through their engaged receptors in a wide spectrum of improved outcomes. The interactive mechanism between psychedelics and receptors in response to mental disorders is still unclear and requires an explanation of which drugs are best suited to initiate a cascade. 5‐HTR: 5‐hydroxytryptamine receptor; AMPAR: α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor; D1R: dopamine D1 receptor; TrkB: tropomyosin receptor kinase B; MDMA: N‐methyl‐3,4‐methylenedioxyamphetamine; LSD: lysergic acid diethylamide; NMDAR: N‐methyl‐D‐aspartate receptor. The figure was created with BioRender.com .

Journal: Advanced Science

Article Title: Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives

doi: 10.1002/advs.202413786

Figure Lengend Snippet: Overview of psychedelic drugs and receptors in mental disorders. Psychedelic drugs, including psilocybin, MDMA, LSD, ketamine, ibogaine, and ayahuasca (DMT as an active component in ayahuasca brew), have renewed interest in treating psychiatric disorders. Emerging psychedelics are harnessed to restore symptoms against poor response rates to traditional medications, such as major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive‒compulsive disorder, autism spectrum disorder (ASD), and substance use disorders (SUD) (e.g., alcohol and opioid). Some psychedelics interact collectively with diverse types or subtypes of receptors, and vice versa, owing to the structural similarities of cognate neurotransmitters. The psychedelics confer potentiation through their engaged receptors in a wide spectrum of improved outcomes. The interactive mechanism between psychedelics and receptors in response to mental disorders is still unclear and requires an explanation of which drugs are best suited to initiate a cascade. 5‐HTR: 5‐hydroxytryptamine receptor; AMPAR: α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor; D1R: dopamine D1 receptor; TrkB: tropomyosin receptor kinase B; MDMA: N‐methyl‐3,4‐methylenedioxyamphetamine; LSD: lysergic acid diethylamide; NMDAR: N‐methyl‐D‐aspartate receptor. The figure was created with BioRender.com .

Article Snippet: ERK, D1R, and c‐fos , , 50 mg kg −1 , IP (Once a day for 7 d) , Male Sprague Dawley rats , Ketamine abuse model was established administration of ketamine IP injection. , Ketamine abusing enhanced the anxious behavior and disrupted NAc , [ ] .

Techniques: Medications